Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ovid Therapeutics (OVID) Non Operating Income (2020 - 2025)

Ovid Therapeutics (OVID) has disclosed Non Operating Income for 5 consecutive years, with $365000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Non Operating Income rose 146.98% year-over-year to $365000.0, compared with a TTM value of $4.5 million through Sep 2025, down 87.69%, and an annual FY2024 reading of $35.5 million, up 410.62% over the prior year.
  • Non Operating Income was $365000.0 for Q3 2025 at Ovid Therapeutics, down from $389000.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $29.0 million in Q2 2024 and bottomed at -$777000.0 in Q3 2024.
  • Average Non Operating Income over 4 years is $3.1 million, with a median of $786086.0 recorded in 2022.
  • Peak annual rise in Non Operating Income hit 1546.15% in 2024, while the deepest fall reached 200.13% in 2024.
  • Year by year, Non Operating Income stood at $668123.0 in 2022, then skyrocketed by 329.08% to $2.9 million in 2023, then tumbled by 48.76% to $1.5 million in 2024, then plummeted by 75.15% to $365000.0 in 2025.
  • Business Quant data shows Non Operating Income for OVID at $365000.0 in Q3 2025, $389000.0 in Q2 2025, and $2.3 million in Q1 2025.